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Title 
Investigating the link between drug-naive First Episode Psychoses (FEPs), weight gain abnormalities and 
brain structural damages: relevance and implications for therapy.  
Aim 
To shed light on the effect that weight gain abnormalities may have on brain structural abnormalities in 
untreated FEPs individuals.   
Hypotheses 
1) Obesity and overweight may increase the severity of those brain structural abnormalities typically 
associated with FEPs, thus potentially leading to a more severe course of illness and to worst 
prognostic outcomes. 
2) Shared vulnerability factors may explain findings on the high rates of obesity and overweight in drug 
naive FEPs.     
3) In FEPs, early interventions aimed at limiting the development of weight gain abnormalities may 
result not only in a reduction of risk of future onset of cardiovascular diseases, type 2 diabetes and 
overall mortality, but also in a limitation of neural network dysfunctions with potential positive 
effects on clinical, cognitive and functional outcomes. 
Relevance  
Despite the high prevalence of being overweight or obese in patients with psychosis spectrum disorders 
(PSDs) and the relationship of obesity to reduced brain volume and poor cognitive and functional 
outcomes in the general population, there are no neuroimaging studies comparing brain volumes in 
overweight or obese patients versus normal weight individuals in the earliest stages of the disorders.  
Shedding light on the association between obesity, PSDs and brain structural abnormalities may have 
relevant implications in terms of prognostic outcomes, especially if the target of the investigation is the 
earliest phase of the disorder, when individuals are less impaired and more amenable to therapeutic 
intervention. 
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Abstract 
 
Evidence suggests that obesity and overweight may be associated with severe brain structural 
abnormalities and poor cognitive and functional outcomes in the general population. Despite 
these observations and the high prevalence of weight gain abnormalities in patients with 
psychosis spectrum disorders (PSDs), no studies has investigated the impact that these metabolic 
disturbances may have on brain structures and development in the earliest stages of PSDs. In the 
present review we shed light on the association between weight gain and brain structural 
abnormalities that may affect the course of illness in drug-naïve FEPs. Given the lack of studies 
directly investigating this issue, we firstly identified and critically evaluated the literature 
assessing weight gain abnormalities and gray or white matter (GM, WM) volumes (either 
globally or in specific regions of interest) in otherwise healthy obese/overweight adolescents and 
young adults. We then compared the results of this systematic review with those of two recent 
meta-analysis investigating GM and WM abnormalities in drug-naïve FEPs. Weight gain in 
otherwise healthy subjects was consistently associated with frontal and temporal GM atrophy 
and with reduced integrity of WM in the corpus callosum. Of relevance, all these brain regions 
are affected in drug-naïve FEPs, and their integrity is associated with clinical, cognitive and 
functional outcomes. The underlying mechanisms that may explain the association between 
weight gain, adiposity, and brain damage in both healthy subjects and drug-naïve FEPs are 
widely discussed. On the basis of this knowledge, we tried: a) to deduce an integrative model for 
the development of obesity in psychosis spectrum disorders; b) to identify the key vulnerability 
factors underlying the association between weight gain and psychosis; c) to provide information 
on new potential targets of intervention.  
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1. Introduction 
Obesity and excessive weight are pervasive problems in patients with psychotic spectrum disorders 
(PSDs), with rates of comorbidity ranging from 40 to 60% in recent studies1,2. Even if multi-episode 
patients are at increased risk compared to first episode patients2, weight gain abnormalities have also been 
often described in the earliest stages of illness with higher prevalence rates compared to those of same-
age general population3–5.  
Reasons for this high prevalence are not fully understood. A complex interplay between unhealthy life-
style, side-effects of medications, and pathophysiological mechanisms innate to the psychiatric illness, 
has been so far the most cited explanation1.   
It is well established that obesity increases the risk for cardiovascular diseases (CVD), type 2 diabetes, 
various cancers, and overall mortality6. This is of particular concern because recent meta-analyses 
demonstrate that these metabolic disturbances contribute to a larger extent to the dramatic increase in 
premature mortality among people with PSDs2,4.  
In addition to their well-known role in increasing risk for various cardio-metabolic conditions, weight 
gain abnormalities have been shown to be associated with brain structural abnormalities in otherwise 
healthy individuals7,8. Obesity/overweight-related brain volume reductions have been detected in a range 
of regions implicated in reward (e.g. striatum, orbitofrontal cortex, insula), emotion and memory (e.g. 
amygdala, hippocampus), homeostatic regulation of intake (e.g. hypothalamus), sensory and motor 
processing (e.g. insula, precentral gyrus), and cognitive control and attention (e.g. prefrontal cortex, 
cingulate)7–10 in obese and overweight individuals.  
Of note, all these brain areas, the associated neural networks, and their physiological functions are often 
disrupted in PSDs11–15. 
Furthermore, a growing body of literature pointed out that: (i) weight gain-related brain abnormalities are 
responsible for poor cognitive and functional outcomes in the general population16,17; and (ii) 
obese/overweight patients with PSDs usually have worse prognostic outcomes compared with their lean 
counterparts18. Taken together, this evidence suggests that obesity and overweight, when expressed in 
comorbidity with PSDs, may increase the severity of those brain structural abnormalities associated with 
core features of the psychiatric disorder, thus leading to a more severe course of illness. In line with this 
hypothesis, a recent series of papers on patients with a first episode mania and a study on subjects at 
familiar risk for psychosis showed that obese vs lean patients have more severe brain structural 
abnormalities and worse prognostic outcomes19,20.  
Shedding light on the association between obesity, PSDs and brain structural abnormalities may thus have 
relevant implications in terms of future clinical outcomes, especially if the target of the investigation is 
the earliest phase of the disorder, when individuals are less impaired and more amenable to therapeutic 
interventions21. Of relevance, longitudinal studies in otherwise healthy individuals show that 
obesity/overweight-related brain structural abnormalities might be reversible with weight loss and dietetic 
interventions, in particular when adolescents and young adults are targeted22–24. In line with this evidence, 
lifestyle interventions for enhancing psychological well-being and weight management have been proved 
to be effective in terms of clinical, cognitive, and functional outcomes in a wide range of psychiatric 
syndromes25,26.  
These observations suggest that early interventions aimed at reducing the negative influence that weight 
gain abnormalities may have on brain structures during the early stages of PSDs may result not only in a 
reduction of cardiovascular risk and future overall mortality, but also in a limitation of brain volume loss 
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in neural networks often associated with clinical, cognitive and functional outcomes of the psychiatry 
illness27.  
Surprisingly, so far no neuroimaging studies have compared brain volumes in patients during the early 
stages of PSDs with or without obesity and overweight.  
 
1.1 Aims 
 
The aim of the present paper is to shed light on the effect that obesity and excessive weight may have on 
those brain structural abnormalities most commonly found in drug naïve patients with a first psychotic 
episode (FEP). We focused on antipsychotic-naïve individuals because, given the well-known pro-
adipogenic effect of antipsychotic medications28, this population provides a unique opportunity to clearly 
understand the nature of the association between the psychiatric illness and the weight gain disturbances.  
 
1.2 Hypotheses 
 
We specifically hypothesize that: (i) obesity and overweight may increase the severity of those brain 
structural abnormalities typically associated with FEPs, thus potentially leading to a more severe course 
of illness and to worst prognostic outcomes; (ii) shared vulnerability factors may explain findings of high 
rates of obesity and overweight in drug naive FEPs; and (iii) in these patients, early interventions aimed at 
limiting the development of obesity/overweight may result not only in a reduction of the risk of future 
onset of cardiovascular diseases, type 2 diabetes and overall mortality, but also in a reduction of brain 
structural damages with potential positive effects on clinical, cognitive and functional outcomes. 
 
 
We thus conducted a systematic review of the literature on brain structural abnormalities in 
obese/overweight otherwise healthy adolescent and young adults. We then compared our findings with 
those reported in the most recent meta-analyses and systematic reviews investigating gray and white 
matter abnormalities in drug-naive individuals with FEP and discuss potential underlying mechanisms of 
obesity-induced brain damages.  
Finally, based on this knowledge, we tried to deduce an integrative model for the development of obesity 
in drug naive-FEP followed by a discussion of potential therapeutic interventions.  
 
2. Methods  
 
2.1 Systematic review  
 
The systematic review was conducted in accordance with the MOOSE guidelines29 and in line with the 
PRISMA statement30, following a predetermined, but unpublished protocol. 
 
2.2 Data sources 
Titles, abstracts and topics were searched using the following terms: “Body Mass Index” OR “Adiposity” 
OR “Waist Circumference” OR “Waist to hip ratio” OR “Body Weight” OR “Obesity” OR 
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“Overweight” AND “Neuroimaging” OR “Gray Matter” OR “White Matter” OR “Brain Volume” OR 
“Magnetic Resonance Imaging” 
The electronic research literature databases included the PubMed and Web-of-Science from inception to 
May 2016. Limits were set to humans and English language. In addition, reference lists and citations of 
initially identified reports were examined. Additional studies were searched manually.  
2.3. Study selection 
Search was carried out independently by three investigators (A.M., A.A., M.F.); disagreements were 
resolved by consensus among these primary raters and the other investigators.  
Articles were considered to be eligible if 1) published in peer-review journals; 2) included at least one 
brain scan; 3) examined global, lobar and regional brain volumes; 4) included at least one anthropometric 
or quantitative assessment of central or global adiposity, such as body weight, BMI, WC, or abdominal 
girth, WHR, visceral adipose tissue (VAT) and/or subcutaneous adipose tissue (SAT), percentage body 
fat and similar indices; 5) focused on the weight spectrum from normal to class III obesity, which did not 
include studies on being underweight; 6) included studies with subjects having a mean age of 17 to 32 
years (adolescents and young adults); 7) included at least 10 participants.  
The age criterion was set in order to obtain comparable data with those from brain imaging meta-analyses 
on drug-naïve patients with FEP. 
Studies were excluded if participants had additional co-occurring metabolic or main 
neurological/psychiatric disorders (including binge eating, anorexia and bulimia nervosa) other than 
overweight/obesity and if they were focused on sample other than the general population (e.g. Prader-
Willis or other genetic causes of obesity; twins’ studies; etc.). 
2.4. Data Extraction  
Data were independently extracted by the three reviewers with a use of a precoded form. The following 
data were extracted from studies meeting the criteria for inclusion in the systematic review: age, gender 
distribution, study design, measure of adiposity, number of subjects (obese-overweight and lean), 
neuroimaging methods, covariates adjustment, and main findings.    
3. Results 
3.1 Systematic review of brain structural abnormalities in obese/overweight otherwise healthy 
adolescent and young adults  
 
The literature search is summarized in Figure 1. Eleven studies10,24,31–39 met our inclusion criteria and 
were included in the present systematic review  (more details are given in Supplementary Material, 
Results).   
The most consistent findings were that obese/overweight otherwise healthy individuals have: (i) lower 
GM volumes of the temporal and prefrontal regions; and (ii) reduced WM integrity in the corpus callosum 
compared to their lean counterparts. Weaker evidence suggests that reduced WM and GM volumes of the 
insula may also be expressed in obese/overweight individuals.    
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A detailed description of findings can be found in Supplementary material, Results and in eTable1 
 
3.2 Brain structural abnormalities in drug-naïve FEPs 
 
We searched for the most recent systematic review and meta-analysis on brain structural abnormalities in 
drug-naïve patients with FEP in PubMed using the following key words: “white matter” OR “gray matter 
AND “schizophrenia” OR “psychosis” AND “first episode psychosis” OR “first episode schizophrenia” 
AND  “diffusion tensor MRI” OR “structural connectivity” OR “structural MRI” OR “neuroimaging”.  
The most consistent findings were that drug-naïve individuals with FEP have: (i) lower GM volumes of 
the right temporal lobe, the left and right insula, and the left cerebellum40; (ii) reduced WM integrity in 
the corpus callosum, the cingulum bundle, the left inferior longitudinal fasciculus, and the left inferior 
fronto-occipital fasciculus41,4243. 
Results are summarized in Table 1 and Table 2. Detailed information is given in Supplementary 
Material, Results. 
 
3.3 Weight gain- and drug-naïve FEPs-related brain structural abnormalities: overlaps   
The most consistent findings suggesting the existence of brain structural abnormalities overlap in FEP 
and obese/overweight individuals include: 1) temporal lobe GM volume; and 2) the interhemispheric WM 
fibers running though the corpus callosum. Sparse and less consistent evidence suggests that the left 
insula may represent another area of overlap (See also Table 1 and Table 2). 
4. Discussion  
4.1 Overall findings  
The first hypothesis of the review was that obese/overweight FEPs might have more severe brain 
structural abnormalities compared to their lean counterparts. In line with this hypothesis, we found that 
weight-gain related brain structural abnormalities in otherwise healthy adolescents and young adults 
frequently overlap with those reported for drug-naïve FEPs by two recent meta-analyses (Table 1 and 2).  
Of relevance and in line with our results, a recent study demonstrated that obese/overweight young adults 
with a familiar risk for PSDs have more severe brain structural abnormalities (i.e., reduced white matter 
integrity) compared to their lean counterpart44s. A detailed discussion of these findings and their clinical 
implications can be found in Supplementary Material, Discussion.  
4.2 Weight gain-induced brain damages: potential underlying mechanisms. Implications for drug-
naive FEPs 
In this section we will review all the potential biological mechanisms that may explain the association 
between obesity/overweight and brain structural abnormalities in healthy individuals. Furthermore, we 
will provide evidence to support the hypothesis that obesity and overweight may contribute to worsening 
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brain structural abnormalities in FEPs by increasing the severity of disease-inherent pathophysiological 
mechanisms typically associated with the psychiatric disorder. 
4.2.1 Cytokines and inflammation 
It is now clearly established that adipose tissue, especially in its visceral/abdominal form, is highly 
metabolically active, producing and releasing hundreds of different compounds, such as adipokines and 
cytokines45, which are directly involved in the pathogenesis of some of the cardiovascular complications 
commonly seen in association with obesity6. Other than their role in increasing cardiovascular risk, some 
of these compounds seem to have a relevant effect on brain structure and development46,47, thus 
potentially playing a role in contributing to brain volume loss in both obese/overweight otherwise healthy 
subjects and FEPs.  
Obesity is characterized by a chronic low inflammation state partly mediated via production of pro-
inflammatory cytokines48. Some pro-inflammatory cytokines may cross the blood brain barrier (BBB) and 
affect brain plasticity and signaling processes47. Among them, the most commonly investigated is 
interleukin IL-649. This cytokine crosses the BBB by a saturable transport mechanism, entering both the 
cerebrospinal fluid (CSF) and brain parenchyma50. The hippocampus is particularly vulnerable to adverse 
effects of IL-6, affecting brain functions like synaptic plasticity and neurogenesis, with a similar effect 
being also described for IL-1β51.  
An early onset of IL-6 elevation due to childhood and adolescent obesity52, and its persistence in aging 
obese adults47, has been proposed to negatively affect brain functioning by inhibiting neurogenesis, 
decreasing synaptic plasticity and subsequently disrupting learning and memory processes, particularly in 
the hippocampus, which may increases the risk of cognitive deficits47,51.  
Meta-analytic evidence shows that drug-naïve FEPs have higher serum or plasma levels of pro-
inflammatory cytokines53, such as IL-1β and IL-654. Some authors have suggested that high levels of pro-
inflammatory cytokines in psychosis could be related to an over-activation of the lymphocytes T-helper 
(Th) type 155, resulting in an imbalance in the Th1/Th2 cytokines ratio, with a shift towards the Th2 
system56. However, other sources may play a relevant role in determining the low-chronic inflammatory 
state often associated with FEPs, with abdominal visceral obesity being one of the most plausible 
candidates45. Furthermore, it has been demonstrated that obesity can induce microgliosis57, a mechanism 
that seems to be tightly related to PSDs since the earliest stages of the disorders58.  
It is possible to hypothesize that obesity and overweight in FEPs may contribute to worsening the low-
grade chronic inflammatory status typically associated with these disorders, with relevant consequences 
on brain structures and development.  
 
4.2.2 Adipokines 
 
Adipokines, with leptin being the most widely investigated in the field of PSDs59, are compounds released 
by the adipose tissue having pleiotropic effects on the body and largely interacting with the central 
nervous system46. Thus, they represent one of the most plausible factors mediating the association 
between obesity/overweight and brain structural abnormalities. Leptin is a pleiotropic hormone 
circulating at levels that are proportional to body adipose stores60, such that to increase in body fat mass 
correspond increased leptin levels. In addition, leptin, that may cross the BBB through a specific 
receptor61, appears to facilitate pre- and postsynaptic transmitter release and sensitivity in hippocampal 
CA1 neurons47 and to modulate mesolimbic dopamine system activity59,62. This may explain findings of a 
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positive association between circulating leptin levels, spatial learning and memory function in healthy 
individuals47, and with response to treatment in FEP63. Of note, there is evidence showing that childhood 
and adolescent obesity may facilitate the development of leptin resistance64, which has been associated 
with brain atrophy, poor cognitive performances, and with increased risk of Alzheimer disease when 
expressed in middle-aged adults47.   
This suggests that obese/overweight vs lean FEPs may be at greater risk to develop leptin-resistance, 
which might have relevant implications on brain structure and development, cognitive functions and 
response to treatment65,66.  
 
4.2.2 Glucocorticoid-induced brain atrophy 
Obesity and overweight are associated with higher circulating cortisol levels67. Many studies have shown 
that higher cortisol levels may induce brain atrophy and worse cognitive performance, with recent 
evidence suggesting that obesity per se, at least in adolescents, mediates the relationship between HPA 
axis abnormalities and atrophy in the hippocampus and frontal lobe68,69.  
Dysregulations of the HPA axis and consequent glucocorticoid signaling abnormalities have been widely 
described in drug-naive FEP and in youths considered “at risk” for future psychosis conversion70,7172. 
These abnormalities may lead to reduced brain volumes in area such PFC, amygdala and hippocampus68, 
by reducing brain derived neurotrophic factor (BNDF) release and increasing glutamate neuro-toxic 
effects73. Based on this knowledge, it is possible to hypothesize that weight gain can worsen HPA 
dysfunctions in FEP leading to more severe brain structural abnormalities.  
 
4.2.3 Insulin resistance 
Physiologically, insulin facilitates cellular glucose uptake into brain tissue, while systemically it regulates 
body weight, energy disposal, food intake and locomotion74. Insulin resistance is one of the most common 
complications of obesity, especially in its abdominal visceral form75,76. 
Impaired cerebral insulin receptor signaling, resulting from the development of obesity-induced insulin 
resistance, may cause disturbances in the uptake of glucose into brain tissue, resulting in cellular glucose 
deprivation, eventually leading to tissue atrophy75,76.  
Of relevance, consistent evidence suggests that impaired glucose abnormalities are expressed in drug-
naïve patients with FEP and are related to higher WHR and WC77. These observations suggest that 
obesity and overweight may contribute to worsening of insulin-resistance phenomena in FEP, with 
potential negative consequences on brain volumes.  
 
4.2.4 Vascular risk factors 
Cardiovascular risk factors other than insulin resistance and abdominal/visceral obesity, such as 
dyslipidemia78, hypertension79, and other components of the metabolic syndrome80 can affect the brain 
vasculature and may contribute to brain volume loss in obese/overweight individuals. In patients with 
FEP, cardiovascular risk factors are present early in the illness and likely related to the underlying illness, 
unhealthy lifestyle, and antipsychotic medications, which interact with each other3. However, evidence 
for a role of hypertension and dyslipidemia as mediators of brain damage during this early stage of illness 
are lacking and it is reasonable to hypothesize that these obesity-related cardiovascular risk factors may 
play a significant role in inducing brain atrophy during later stages of PSDs.   
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4.2.5 The gut microbiome 
The gut microbiome has received greater attention during the last few years as a potential mediator of gut-
brain interactions81,82.  Despite a significant interpersonal variation in the enteric microbiota, there seems 
to be a balance that confers health benefits, and alteration in beneficial bacteria can negatively influence 
both mental and physical well being82,83. 
Obesity is closely tied to changes in the composition of the intestinal microbiota. In animal models of 
obesity, the interplay between the dominant gut phyla, Bacteroidetes and Firmicutes, is shifted with a 
significant reduction of the former and a corresponding increase in the latter81. The shift in the relative 
abundances of these phyla has been associated, among several factors, with a diet rich in high saturated 
fats and calories, high fructose consumption, and an increased sensitivity to stress (through the HPA 
axis), all factors that are closely related to PSDs since the earliest stages of the disorders81,84. 
The influence of the microbiota extends beyond the gastrointestinal tract, playing a major role in the 
development and functioning of the central nervous system83. Obesity-induced modifications on the 
microbiome may have a significant impact on brain functions82,85. It is now clear that a broad range of 
bacteria manufacture and secrete neurochemicals that are essential for brain structure and development. A 
growing body of literature shows that γ-Aminobutyric acid (GABA), dopamine, serotonin, norepinephrine 
and acetylcholine are produced by different strains of gut bacteria, such as Lactobacillus, 
Bifidobacterium, Saccaromyces, Bacillus, and Serratia (see Dinan and colleagues for an extensive 
review85). Furthermore, evidence suggests the existence of an interplay between alterations in the 
microbiome, HPA axis dysregulation, and increased pro-inflammatory cytokines release81. Stress and 
glucocorticoids alter the permeability of the gut barrier, allowing lipopolysaccharide, an essential 
component of gut gram-negative bacteria, and other molecules to gain access in the blood stream 
stimulating immune activation through Toll-like receptors and release of pro-inflammatory cytokines (e.g. 
IL-6 and IL-1β)83, which circulating levels may contribute to brain volume loss in both FEPs and 
otherwise healthy obese individuals.  
Even if the evidence is mostly preclinical, it is reasonable to hypothesize that weight gain-induced 
variation in the gut microbiota may represent an additional factor contributing to the development of brain 
structural abnormalities in obese/overweight adolescents and young adults and to more severe brain 
volume loss in obese/overweight vs lean FEPs.  
 
4.3 The path to weight gain abnormalities in psychotic disorders before antipsychotic exposure: 
evidence from drug-naive FEP.  
 
It is undeniable that exposure to APDs, especially atypical APDs such as clozapine and olanzapine, 
constitute one of the major contributing factors to the development of obesity and overweight in patients 
with psychotic-spectrum disorders86. However, accumulating evidence indicates that such abnormalities 
cannot solely be accounted for by APDs exposure because they occur (albeit in a somewhat less severe 
form) already in drug naïve or minimally medicated first episode patients87–89. This suggests that at least a 
part of the vulnerability to develop weight gain disturbances in psychotic-spectrum disorders might be 
related to mechanisms innate to the psychiatric illness89.   
In this section, firstly, we will briefly summarize evidence for weight gain abnormalities in drug-naive 
patients with FEP, and provide a definition for heterogeneous conditions such as obesity and overweight. 
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This clarification is of particular relevance given the influence that different measurements of weight gain 
abnormalities may have on findings on FEPs individuals, and their importance in terms of both general 
and mental health.  
Secondly, we will show that most of the vulnerability factors underlying obesity and overweight 
(especially in their abdominal form) in otherwise healthy individuals are tightly related to psycho-physio-
pathological mechanisms of psychosis spectrum disorders expressed prior of APDs exposure. This 
observation suggests that innate mechanisms of psychiatric illness may represent key vulnerability factors 
for the development of weight gain abnormalities in FEPs.  
Thirdly, we will discuss how some specific neural network dysfunctions, typically associated with 
psychotic spectrum disorders since their earliest stages, may facilitate the onset of weight gain 
abnormalities triggering this pre-existent vulnerability.  
Finally, implications for treatment will be discussed.  
 
4.3.1 Defining weight gain abnormalities in drug-naive FEPs: the importance of body fat distribution, 
beyond the body mass index.  
 
Obesity and overweight are generally defined by an excess of body fat and are most often estimated by 
the ratio of weight over height, the most commonly used anthropometric index being the Body Mass 
Index (BMI)90.  
However, weight gain abnormalities are heterogeneous conditions, with measurement methods varying 
accordingly across different studies. Such heterogeneity appears to be explained, to a very significant 
extent, by individual differences in regional body fat distribution, particularly in abdominal/visceral 
adipose tissue91,92. Abdominal visceral obesity, as measured by proxy indicators such as waist to hip ratio 
(WHR), Waist Circumference (WC) and hyper-triglyceridemic waist93 (HTW, a measure resulting from a 
combination of WC size and triglyceride blood levels), is more strongly related to metabolic 
complications, brain structural abnormalities and to cardiovascular outcomes than BMI6.  
For these reasons, distinguishing between different types of weight gain abnormalities is of particular 
relevance for future studies investigating the underlying mechanisms of the association between obesity, 
overweight and brain structures in drug-naive FEPs. Furthermore, this differentiation allows identifying 
more relevant targets in terms of novel diagnostic and interventional strategies.     
In line with these considerations, recent studies demonstrate that more than a higher BMI, drug-naive 
patients with FEP are more likely to have a metabolically unfavorable body composition, comprising 
greater WC and WHR, high fat percentage and low muscle mass when compared to same-age general 
population4,94. These findings were confirmed in a recent meta-analysis on drug naïve individuals with 
FEP suggesting that these patients “may have a higher waist to hip ratio and more intra-abdominal fat 
relative to BMI than healthy controls”4. Even if higher BMI in drug-naive FEP is a replicated (but not 
always consistent) finding, meta-analytic evidence failed to find enough statistical power to demonstrate 
significant differences with the general population2, highlighting the need of more studies investigating 
the link between psychosis-spectrum disorders and weight gain abnormalities in the pre-antipsychotic 
stages of the psychiatric illness.   
 
4.3.2 Abdominal obesity in drug-naive FEP: vulnerability factors  
 
Abdominal obesity and psychosis-spectrum disorders shared a surprising number of vulnerability factors. 
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Most of these factors are tightly linked with PSDs and expressed at illness onset, even in never medicated 
patients. This suggests that patients with PSDs may have an innate vulnerability to develop abdominal 
obesity that is, at least partially, independent of APDs exposure.  
Starting from a really comprehensive list of etiopathogenetic factors of abdominal obesity in the general 
population (widely reviewed by Tchernof and Després93), we highlight differences and commonalities 
with findings on psycho-physio-pathological mechanisms often expressed in drug-naive FEP.  
Of note, some of the identified vulnerability factors might be easily targeted with both pharmacological 
and non-pharmacological interventions (see section 4.5). These interventions might significantly reduce 
the risk of developing weight gain abnormalities and their negative consequences on both mental and 
general health during a critical, early stage of the psychiatric illness95.   
 
Gender 
Human males and females greatly differ in terms of body fat distribution. Evidence indicates that the 
amount of visceral adipose tissue is up twofold higher in men than in premenopausal women, even after 
correcting for total body fat mass96.  Indeed, even if for a given body mass index men usually have more 
lean mass and women higher adiposity, adipose tissue in men is usually located around viscera while in 
women in peripheral or subcutaneous storages97. 
Gender differences have been reported in various aspect of PSDs, including epidemiology, clinical 
course, and response to antipsychotic medications (see Markham for an extensive review98). In particular, 
men are approximately 40% more likely to develop a FEP compared to women, have a earlier age of 
onset, more severe illness course, more negative symptoms, poorer response to antipsychotic treatment, 
and possibly greater brain structural abnormalities98. 
 
Sex Hormones 
Gender differences observed in psychosis-spectrum disorders98 and abdominal obesity99 can be partly 
accounted for by altered levels of sex steroid hormones. In otherwise healthy men, low plasma levels of 
total testosterone100, sex hormone-binding globulin (SHBG, a determinant of testosterone 
bioavailability)101, are generally associated with visceral obesity and a greater number of metabolic 
syndrome features102. Similarly, drug-naive men with FEP have lower levels of testosterone, and there is 
an inverse relationship between testosterone levels and severity of negative symptoms98. Association 
studies that address circulating androgens and body fat distribution in otherwise healthy women are 
equivocal103,104. In some studies, high total or free plasma testosterone levels are positively associated 
with visceral fat accumulation103. However, others have reported negative associations104, and some failed 
to observe any correlation105. Limitations in the measurement of androgens levels in women may possibly 
explain these discrepancies6. 
Blood levels of estrogen seem to play a role in both FEPs and visceral obesity as well. In both otherwise 
healthy men and women low levels of estrogens seem to be related to increased body weight and visceral 
fat accumulation6. This observation is of particular relevance because of the well-known protective effect 
of estrogens against psychoses98,106. Indeed, several authors showed an inverse relationship between 
circulating estradiol levels and severity of psychotic symptoms, cognitive impairments, and antipsychotic-
resistance in patients with psychotic spectrum disorders106.  
 
Genetics  
 12 
A recent systematic review by Malan-Muller and colleagues107 aimed at identifying genetic variants 
potentially contributing to the high comorbidity between metabolic syndrome (MetS) and schizophrenia. 
Among those genes that showed strong evidence for an association with MetS, some were specifically 
associated with weight gain abnormalities in schizophrenia. Specifically: α2A adrenergic receptor gene 
(ADRA2A); insulin-induced gene 2 (INSIG2); leptin-receptor gene (LEPR); and fat mass and obesity 
associated gene (FTO). Minor evidence coming from single study analyses were also available for 
endocannabinoid receptor type 1 gene (CNR1) and BDNF gene polymorphisms that, of note, have been 
implicated in the pathophysiology of schizophrenia107.  
Ethnicity  
Ethnic differences may influence both body fat distribution and severity of illness in psychotic spectrum 
disorders. 
A review of 8349 published studies on abdominal obesity showed that, for a similar level of total 
adiposity, Asians have the highest propensity to develop visceral abdominal obesity, with Caucasians  
intermediate between Asians and Black-Africans, which have the lowest risk6.  
A similar stratification of risk has been reported by one of the earliest studies investigating the association 
between ethnicity and severity of illness in psychotic-spectrum disorders108. However, subsequent cross-
ethnic empirical studies of individuals with schizophrenia and related-psychosis have produced 
inconsistent findings109.  
The Endocannabinoid system  
Recent evidence suggests that the endocannabinoid system is chronically activated in otherwise healthy 
obese individuals110,111. Of interest, dysregulation of the endocannabinoid system  to be preferentially 
associated with visceral obesity rather than with overall adiposity112,113. Type-1 cannabinoid receptors 
(CB1) are highly expressed in visceral adipose tissue114. Furthermore, CB1 agonists, such as anandamide 
and 2-arachidonoylglycerol, activate adipogenesis and prolipogenesis110, thus contributing to visceral fat 
accumulation.  
A growing body of literature suggests that the endocannabinoid system is altered in PSDs115.  
Clinical studies in patients with PSDs demonstrated: (i) elevated levels of the endocannabinoid 
anandamide in the cerebrospinal fluid and serum of untreated patients with schizophrenia and 
antipsychotic naive FEP116,117; and (ii) increased density of CB1 receptors in the dorsolateral prefrontal, 
anterior cingulate, and posterior cingulate cortices, brain regions involved in core dysfunctional 
psychopathological processes of PSDs115,118.   
Dysfunctions of this system, which has been shown to interact and promote dysregulations of core 
neurotransmitter systems (i.e., dopamine and glutamate), seem to play a key role in triggering psychotic 
onset and relapses115,118. 
 
Hypothalamo-Pituitary-Adrenal Axis (HPA), Stress, and Glucocorticoids 
Excessive circulating glucocorticoids concentrations, as observed in Cushing’s syndrome, create a 
pathological phenotype of abdominal obesity, dyslipidemia, insulin resistance, and hypertension119,120. 
These observations led several authors to hypothesize a central role for HPA dysfunction in the 
development of abdominal obesity in otherwise healthy individuals.  A number of studies and review 
articles93,102 suggest that chronic stress or poor coping in stressful situations is associated with mild 
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hypercortisolemia, and prolonged sympathetic nervous system activation, which in turn could favor 
accumulation of visceral fat.   
Of note, HPA dysfunction have been proposed as a trait-marker of PSDs, being expressed since the 
earliest stages of the disorders and being not modifiable with psychotropic treatment70,121,122. A specific 
pattern of HPA abnormalities has been described in FEP, as characterized by: a) blunted Cortisol 
Awakening Response (CAR)70; b) reduced HPA response to stress123; and c) increased blood cortisol 
levels throughout the day70. Some of these abnormalities, in particular a blunted CAR and a reduced HPA 
response to stress, are expressed in drug naive patients and have been associated with core features of 
PSDs, such as severity of positive symptoms and cognitive decline124.  
Another recognized etiologic factor for abdominal obesity in otherwise healthy individuals is the 
increased local cortisol synthesis in adipose tissue. Local production of glucocorticoids by adipose tissue 
11β-hydroxysteroid dehydrogenase  (11β-HSD) has been clearly linked to the development of abdominal 
obesity in animal models and associated to increased visceral fat accumulation as well as with 
concomitant metabolic alterations in humans125,126. Of relevance, an increased activity of 11β-HSD, which 
converts local inactive cortisone to active cortisol, has been found in large samples of patients with 
PSDs127,128, further highlighting the existence of a tight link between the glucocorticoids axis and body fat 
disposition in these patients.       
Dietary habits 
Apart from the obvious association between high caloric intake and obesity, few studies have investigated 
which specific nutritional factors might predispose to visceral fat accumulation in the general population. 
Animal studies have shown that saturated fat intake is associated with preferential accumulation of 
visceral fat and development of insulin resistance compared to other fatty acids129. In humans, fructose 
appears as one of the only nutrients that has been demonstrated to potentially affect body fat distribution 
independent of its impact on overall adipose tissue accretion, with mechanisms that have been widely 
reviewed elsewhere130,131.   
Of note, patients with PSDs often follow a dietary pattern rich in saturated fat, calories and fructose132.  
Despite this unhealthy dietary pattern can be a consequence of lifestyle related factors (i.e., low socio-
economical status, smoking habits, and antipsychotic side effects), studies on drug naive and "at risk 
mental state" individuals suggest that disease-inherent neurobiological mechanisms may also play a key 
role133,134 (see 4.3.3).  
Sedentary Life Factors/Physical Inactivity 
A sedentary lifestyle could obviously contribute to the onset of weight gain abnormalities. What is 
interesting is that physical activity/exercise can selectively or at least preferentially reduce abdominal 
visceral adiposity, as shown by a review work by Ross and Janiszewski135. The authors suggest that 
regular physical exercise can induce a substantial reduction of visceral fat accumulation even in the 
absence of weight loss. 
Several studies136 and recent meta-analytic evidence137 suggest that patients with PSDs have a more 
sedentary life and exercise less than the general population. Of relevance, a recent review suggests that 
also prodromal individuals have consistently lower levels of physical activity and exercise at a lower 
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intensity than controls133, with a birth cohort study showing that those who later developed psychosis 
were more likely to be inactive during adolescence than those who did not138.  
The microbiome 
As briefly reviewed in section 4.2.5 weight gain abnormalities are often linked to significant shifts in 
microbiome balance. Of interest, a shift in the relative abundances of the two dominant phyla (i.e., 
Bacteroides and Firmicutes) has been also associated with schizophrenia-like behavior in preclinical 
studies84. The shift in the relative abundances of these phyla can be caused, among several factors, by a 
diet rich in high saturated fats and calories, high fructose consumption, and an increased sensitivity to 
stress (HPA axis dysregulations)81, which are all related with disease-inherent processes of psychotic-
spectrum disorders83 and expressed at illness onset even in never medicated patients.  
Despite evidence suggesting a link between the gut microbiota composition and mental health is mostly 
preclinical, some clinical studies already demonstrated that administration of probiotics to babies 
significantly reduced the development of severe mental illnesses, such autism and ADHD, up to 13 years 
later85. For this reason, it is likely that findings suggesting that microbiome shifts may play a significant 
role in both PSDs and weight gain abnormalities will be replicated also in future clinical studies.  
 
In summary: (i) male sex; (ii) low levels of androgens in men ad lower levels of estrogens in both men 
and woman; (iii) specific genetic polymorphisms; (iv) higher circulating levels of endocannabinoids and 
increased CB1 expression; (v) hypercortisolemia and increased activity of 11β-HSD-1; (vi) lack of 
physical activity; (vii) poor dietary-habits; and (viii) shifts in the microbiome composition, represent key 
vulnerability factors for the development of abdominal obesity in psychotic spectrum disorders. Of 
relevance, all the mentioned factors are expressed at illness onset and in drug-naïve individuals. This 
observation further suggests that patients with FEPs might have an innate vulnerability to develop 
abdominal obesity, with its relevant consequences on both general and mental health.  
 
4.3.3 Abdominal obesity in drug-naïve FEPs, triggering factors: unmasking the vulnerability 
 
APDs play a relevant and undeniable role in unmasking the vulnerability to develop weight gain 
abnormalities in psychotic spectrum disorders. However, some of the triggering factors that might start 
the path to visceral fat accumulation in FEPs are independent of APDs medications. Based on a consistent 
body of literature, it is possible to hypothesize that the unhealthy lifestyle choices (i.e., dietary patterns 
and reduced physical activity) that trigger those mechanisms leading to the development of obesity and 
overweight in FEPs are consequent to specific neural network dysfunctions associated with disease-
inherent mechanisms of psychosis.  
As for most of the vulnerability factors, these triggers are present at illness onset and even in never 
medicated patients.   
 
A “sluggish” reward system and a reduced inhibitory control  
As previously highlighted, consistent evidence suggests that patients with PSDs are more likely to 
consume highly palatable food, which is often rich in saturated fat, fructose and calories. This unhealthy 
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life-style choice can be surely explained by the well know appetite-stimulating effect of APDs. However, 
the preference for highly palatable food in patients with PSDs seems also to characterize drug-naïve 
individuals. This observation suggests that mechanisms other than APDs may play a role in this unhealthy 
life style choice. A fascinating hypothesis stem from a comprehensive review by Elman et al.12 in which 
the authors suggest that psychosis-spectrum disorders and unhealthy food preferences may be potentially 
explained by recursive partly shared neural systems. The mesolimbic hyper-dopaminergic state, a key 
neuro-pathological feature of the psychotic-spectrum, presumably renders the incentive reward system 
insensitive to less salient and palatable nutrition (e.g. vegetables). Furthermore, according to the authors, 
palatable food may produce dysregulated dopamine release in the ventral striatum, creating a rigid 
motivation state fixated on procurement of this type of food. These mechanisms, together with poor 
cognitive control from a hypofunctional PFC (involved in the inhibitory control of overeating behavior), 
may provide an explanation for the increased intake of palatable food in patients even before APDs 
exposure12, being expressed in the earliest stages of PSDs and independent of medications139–141.  
Central insulin resistance 
Post-mortem studies show a decreased expression of cerebral insulin receptors (β-subunit), a reduced 
activity of the signal transduction protein Akt1, and a diminished neuronal expression of insulin-
degrading enzyme in the dorsolateral prefrontal cortex of PSDs individuals142–145. These changes may 
cause disturbances in neural glucose uptake and utilization, as suggested by measurements of elevated 
CSF glucose levels146. In vivo fluorodeoxyglucose positron emission tomography (FDG-PET) and 
functional magnetic resonance imaging (fMRI) studies also demonstrate impaired cerebral glucose 
utilization in brain areas that are important in the pathogenesis of schizophrenia, resulting in the 
“metabolic disconnection” of the dorsolateral prefrontal cortex and mediodorsal thalamus with the limbic 
system147. These findings have been interpreted by some authors in light of the “selfish brain” theory75. 
This theory describes the tendency of the human brain to cover its own, comparably high-energy 
requirements with the utmost priority when regulating energy fluxes within an organism. In this respect, 
the brain is thought to behave selfishly148,149. Given the assumption of disrupted cerebral energy supply in 
PSDs due to cerebral insulin resistance, the “selfish brain” theory may provide another, complementary, 
explanation for the preferred intake of high carbohydrate, high fat foods and diminished physical activity 
and exercise in psychotic patients as a way to improve the brain's energy supply.   
4.4 A complex interplay generating a vicious cycle 
All the listed vulnerability and triggering factors are mutual influencing. The mentioned weight-gain 
related dysregulations of bio-behavioral systems and their bio-mediators (insulin, cortisol, cytokines, 
metabolic and sex hormones) dynamically interact and worsen each other150,151. Of relevance, this chronic 
dysregulated state may in turn negatively impact neurogenesis and brain plasticity through both direct and 
indirect processes151,152.  
These mechanisms can be considered nodes of a vicious circle (Figure 2) that can be triggered and fed 
since the earliest stages of PSDs, being at least partially (or originally) independent of APDs exposure 
and likely related to a disease-inherent vulnerability.  
 
4.5 Breaking the cycle: potential strategies for early intervention  
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Most of the nodes of this vicious cycle are modifiable and thus amendable to therapeutic interventions 
(see Figure 2). Antipsychotic medications remain the cornerstone of treatment in PSDs and FEP. For this 
reason, the well-know proadipogenic effect of APDs needs to be taken into consideration when discussing 
available therapeutic options to reduce the risk of developing obesity in FEPs. Thus, the list of potential 
interventions provided below should not be considered as mono-therapeutic options, but as a list of 
complementary interventions to APDs. These add-on therapies should aim at limiting the risk of 
developing weight gain abnormalities and visceral fat accumulation often unmasked by APDs, thus 
reducing the weight gain-related negative consequences on both mental and general health.  
Antipsychotic medications: timing and choice 
As extensively reviewed elsewhere153, antipsychotic medications greatly differ in terms of ability to 
induce weight gain abnormalities. Thus, the choice of the antipsychotic represents the first-line strategy to 
reduce the risk of visceral fat accumulation in FEP. Among APDs, haloperidol, ziprasidone, lurasidone 
and aripripazole seem to be the better options in terms of metabolic tolerability compared to other drugs 
such as olanzapine, risperidone, clozapine, and paliperidone153. It has to be noted that the development of 
significant weight gain abnormalities in FEP may occur since the earliest weeks after APDs exposure3, 
and recent evidence suggests that the critical period for intervention is the first year of treatment95. 
Sex hormones therapies 
The protective effect of estrogen in schizophrenia is well researched and is hypothesized to be the result 
of its neuroleptic-like effect on the dopamine system154. Adjunctive estrogen therapy has been shown to 
be effective in enhancing the treatment of schizophrenia in women155. In men, consideration of estrogen 
therapy has been impacted by concerns of feminization. The development of new estrogen compounds - 
Selective Estrogen Receptor Modulators (SERMs), such as bazodoxifene and lasofoxifene - which do not 
cause feminization, opens up a potentially new and safe treatment strategy for men suffering from 
PSDs154,156. Furthermore, and relevant for the aims of this review, these compounds may also limit the 
development of weight gain abnormalities in FEP, given that low circulating blood levels of estrogens in 
both men and women are associated with increased risk of weight gain and visceral fat accumulation6 (see 
4.3.2) 
Cannabidiol 
As mentioned in section 4.3.2 drug-naive individuals with FEP often have increased serum and CSF 
levels of CB1 receptors agonist115 (e.g., anandamide) and increased CB1 density in the prefrontal brain 
areas118; the magnitude of these abnormalities is positively associated with symptoms severity117,157, and 
evidence from healthy subjects6 suggests that they can also increase the risk of developing weight gain 
abnormalities in these patients (see 4.3.2). Findings from a recent study by McGuire and colleagues show 
that APDs augmented with cannabidiol, a CB1 antagonist, may have relevant beneficial effects on 
clinical, cognitive and functional outcomes of patients with schizophrenia158. Given its action on CB1 
receptors, cannabidiol augmentation strategies may also have a relevant benefit in reducing the risk of 
development of weight gain abnormalities and visceral fat accumulation in FEP.  
Anti-glucocorticoid treatment 
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HPA abnormalities are associated with both PSDs123,134 and risk of developing visceral obesity6 (see also 
4.3.2). Of note, a recent study investigated the effects of antiglucocorticoid treatment (mifepristone, 
RU486) on cognitive outcomes in patients with bipolar depression159. The authors showed that treatment 
with mifepristone reduce CAR abnormalities and improve spatial working memory performance in these 
patients. Therefore, APDs augmented with antiglucocorticoid may represent a new interesting therapeutic 
strategy to ameliorate psychotic symptoms and improve cognitive function in FEP, having also potential 
implications in reducing the risk of developing weight gain abnormalities and visceral fat accumulation.  
Physical exercise 
Meta-analytic evidence suggests that aerobic physical exercise can reduce severity of symptoms 
(negative, positive, and general), improve cognitive performances (in particular, processing speed), and 
lead to better functional outcomes in patients with schizophrenia160. A growing body of literature has 
shown that physical exercise results in increases in several growth factors in the brain, including BDNF, 
which in turn has a positive effect on neurogenesis, synaptic plasticity, and regional brain volume and 
integrity161–163. This effect, as shown by Mueller et al.24 (see Table 1), appears to be associated with a 
reduction of BMI and leptin blood levels. These findings suggest that aerobic physical exercise 
intervention may ameliorate outcomes of PSDs and FEPs by having a positive influence on brain health 
and cognition, as recently demonstrated by several recent studies161–163.  
Diet and probiotics 
It is already well known that specific dietetic interventions may significantly help in reducing the risk of 
cardiovascular accidents in patients with PSDs132,164. Of note, recent evidence suggests that dietary habits 
may also have a relevant impact on brain structural and cognitive outcomes in these patients22. Several 
studies have shown that particular types of food (omega 3 fatty acid, dietary polyphenols, and curcumin) 
and a low caloric and fructose intake may have beneficial effects on brain structures and cognitive 
functions by reducing oxidative stress levels and increasing neural plasticity130,131,165. Furthermore, it is 
known that high doses of omega-3 in prodromal individuals may play a role in delaying or preventing 
psychotic-onset through their positive effects on brain plasticity and inflammation166. Finally, a growing 
body of literature is now investigating the effect of probiotics on gut-microbiome composition and mental 
health, with encouraging preliminary evidence. In particular, positive effects on cognitive and clinical 
outcomes in severe mental illnesses have been demonstrated for B.infantis, L.Helveticus, B. Longus, and 
L.casei; these results led some authors to coin the term “psychobiotics”85. A diet characterized by 
consumption of probiotics, high doses of omega 3 fatty acid, polyphenols, curcumin, and low intake of 
calories and fructose may thus represent a novel and intriguing add-on therapy to prevent or reduce 
visceral fat accumulation in FEPs, limiting its negative consequences on brain structure, clinical, 
cognitive, and functional outcomes.  
Psychotherapy 
Evidence suggests that Cognitive Behavioral Therapy (CBT), and psycho-educational interventions may 
play a role in limiting dysfunctional behaviors (i.e. sedentary life style, dietary habits)25,167 leading to 
weight gain abnormalities in FEPs. Furthermore, a growing body of literature pointed out that the bio-
behavioral system dysregulation associated with obesity and overweight may be targeted indirectly with 
specific therapeutic interventions aimed at increasing resilience and reducing allostatic load26,168. In 
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particular, Well-Being Therapy (WBT) has been shown to be effective in normalizing HPA dysfunctions 
and proinflammatory status in a range of both mental and physical disorders169–171. This may in turn affect 
neurogenesis and improve neuroprotection (reviewed by Charney172).  
4.6 Future directions 
First, future studies should directly investigate if weight-gain abnormalities and in particular visceral fat 
accumulation, as measured by proxy  (WC, WTC, or HTW) or direct (CT, MR) indices, might be 
associated with more severe brain damages when expressed in comorbidity with FEP; their relevance in 
terms of cognitive and functional outcome should also be addressed.  
Second, predictive factors of visceral fat accumulation in FEPs after the first exposure to APDs should be 
identified. Sex hormones, gender, ethnicity, HPA and endocannabinoid system abnormalities, gut-
microbiome composition, genetics, dietary habits and sedentary life style should be all taken into account 
(see section 4.3). 
The identification of the key predictive factors of visceral fat accumulation in FEP is of particular 
relevance given that the first line therapy of these disorders is represented by APDs, which have a well-
known proadipogenic effect. Once identified, these factors may be specifically targeted since the first 
weeks of APDs exposure (see section 4.6). Again, limiting the development of weight gain and visceral 
fat accumulation in FEPs might have relevant implications in terms of both general and mental health.  
5. Conclusion  
 
In the present review we tried to shed light on those weight gain-induced brain structural abnormalities 
that may affect the course of illness in individuals with FEP. Given the lack of studies directly 
investigating this issue, we started our review with a systematic review of the literature on brain structural 
abnormalities in obese/overweight otherwise healthy adolescents and young adults. We then compared 
the results of this systematic review with meta-analytic evidence on brain structural abnormalities in drug-
naïve FEPs.  
We showed that it is possible to hypothesize that obese/overweight vs lean FEPs may develop more 
severe brain structural abnormalities in areas such as temporal lobes, prefrontal regions, insula, and 
corpus callosum, which are tightly related to clinical, cognitive and functional outcomes of the psychiatric 
disorder. Weight gain and visceral fat accumulation may trigger a cascade of events, including central 
insulin and leptin resistance, HPA dysfunctions, gut-microbiome alterations, and low-grade inflammation 
that are potentially responsible for brain structural damages in obese and overweight individuals. Of 
relevance, all these factors are expressed in FEPs before the exposure to APDs. Development of obesity 
and overweight in FEP may thus contribute to worsening these pathophysiological mechanisms, resulting 
in more severe brain structural abnormalities and poorer prognostic outcomes.  
Furthermore, most of the vulnerability factors associated the with risk of developing weight gain 
abnormalities and visceral fat accumulation in the general population also represent key 
psychopathological dimensions typically associated with disease-inherent mechanisms of psychotic-
spectrum disorders, independent of APDs. These compounds surely play a key role in unmasking this pre-
existent vulnerability, but others innate neurobiological mechanisms, expressed since the earliest stages of 
PSDs and in individuals never exposed to medications, may also explain why obesity and overweight are 
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often associated with FEP. Of relevance, these mechanisms may be specifically targeted with both 
pharmacological (sex hormones, anti-glucocorticoids, cannabidiol) and non-pharmacological (diet, 
probiotics, physical exercise, CBT) interventions.  
Weight gain and visceral fat accumulation may significantly influence prognosis in FEP not only in terms 
of future-onset CVD and overall mortality, but also in terms of poor cognitive, symptomatic and 
functional outcomes through specific effects on brain structures and development.   
 
Limitations 
 
This review has several limitations. First of all, it was not possible to perform a quantitative synthesis of 
the results from different studies. Meta-analysis provides a pooled estimate based on statistical analysis of 
results from primary studies and meta-analysis of well-conducted studies is considered to be a superior 
level of evidence. Second, the age range of the studies investigating brain structural abnormalities was 
chosen arbitrarily, with the aim of achieving results that were comparable with those on drug-naïve FEPs.  
 
Figure Legend 
Figure 1. PRISMA Flow chart 
Figure 2. The picture represents the complex interplay between modifiable vulnerability factors (in 
green) and triggering mechanisms (in red) that might explain why patients with FEPs often develop 
weight gain abnormalities. Obesity and overweight, especially in their abdominal/visceral form, may 
contribute to worsening a series of pathophysiological mechanisms typically associated with psychosis 
spectrum disorders and potentially responsible for more severe brain structural abnormalities in 
obese/overweight vs lean FEPs (more details are given in the main text). It could be possible to reduce the 
risk of developing weight gain abnormalities in FEPs through specific interventions (red crosses) 
Figure 2-Legend. Green: modifiable vulnerability factors; Red: triggers; CSF: Cerebrospinal fluid; CAR: 
Cortisol Awakening Response; HPA: Hypothalamo-Pituitary-Adrenal Axis; SERMs: Selective Estrogen 
Receptor Modulators; CBT: Cognitive Behavioral Therapy; WBT: Well-Being Therapy; PFC: Prefrontal 
cortex  
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